Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 65Years
All Genders
NCT04520178

Effects of 5HTP on the Injured Human Spinal Cord

Led by University of Alberta · Updated on 2025-08-27

30

Participants Needed

2

Research Sites

339 weeks

Total Duration

On this page

Sponsors

U

University of Alberta

Lead Sponsor

W

Wings for Life

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study will assess how the serotonin precursor, 5-HTP, alter nervous system excitability and motor function in individuals with spinal cord injuries of differing chronicity and severity. Participants will visit the lab on 4 separate occasions where they will be administered four different drugs in a randomized, double-blinded, placebo-controlled crossover design.

CONDITIONS

Official Title

Effects of 5HTP on the Injured Human Spinal Cord

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must have suffered trauma to the spinal cord at least six months ago or longer
Not Eligible

You will not qualify if you...

  • Individuals with damage to the nervous system other than to the spinal cord
  • Pregnant and/or breastfeeding women
  • Alcoholic participants
  • History of seizure or epilepsy
  • History of suicidal thoughts or behaviors
  • Known or suspected allergy to the medication ingredients
  • Cardiovascular disease including history of heart attack or heart rhythm irregularities
  • Coronary artery disease
  • Reduced liver function or disease
  • Reduced kidney function or disease
  • Lung disease
  • Comatose or depressed states due to CNS depressants
  • Endocrine dysfunction
  • Blood dyscrasias or blood related disease
  • Bone marrow depression
  • Hypocalcemia
  • History of stomach ulcers
  • Wide angle glaucoma
  • Phenylketonuria
  • History of tumors
  • Uncontrolled heart problems
  • Unstable psychiatric or mental disorder
  • Participants taking monoamine oxidase inhibitor therapy
  • Participants taking serotonergic antidepressants
  • Participants taking tricyclic antidepressants
  • Participants taking any type of serotonergic agonist
  • Participants taking dopamine D2 receptor antagonists
  • Participants taking amphetamine
  • Participants taking CNS depressants
  • Participants taking levodopa
  • Participants taking lithium
  • Participants taking anti-hypertensive drugs
  • Participants taking iron salts
  • Participants taking metoclopramide
  • Participants taking phenothiazine medication

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University of Louisville

Louisville, Kentucky, United States, 40292

Completed

2

University of Alberta

Edmonton, Alberta, Canada, T6G-2E1

Actively Recruiting

Loading map...

Research Team

J

Jessica D'Amico, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here